Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Bluestem Capital

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 27
Average round size
info
The average size of a deal this fund participated in
$16M
Portfolio companies 18
Rounds per year 0.82
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 5
Key employees 2
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Medical
  • Medical Device
  • Pharmaceutical
  • Robotics
Summary

The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Sioux Falls.

Deals in the range of 5 - 10 millions dollars are the general things for fund. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Bluestem Capital works on 8 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2018. The real fund results show that this VC is 33 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Bluestem Capital, startups are often financed by PrairieGold Venture Partners, Serra Ventures, Edgewater Private Equity Fund. The meaningful sponsors for the fund in investment in the same round are PrairieGold Venture Partners, Edgewater Private Equity Fund, Visionary Venture Fund. In the next rounds fund is usually obtained by PrairieGold Venture Partners, Sanderling Ventures, Social Capital.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Health Care. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Conventus Orthopaedics, Worldtrak, Ambient Clinical Analytics.

Besides them, we counted 2 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Bluestem Capital:
Typical Co-investors
Bluestem Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Bluestem Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allbirds California, San Francisco, United States
BRJ Ventures -
Castle Harlan Inc. New York, New York, United States
Centerfield Capital Partners Indiana, Indianapolis, United States
China Everbright Investment Management China, Hong Kong, Hong Kong Island
DART Capital Partners -
Fetzer Institute -
Fish Taco Ventures Indiana, Notre Dame, United States
Heartis Corporation Japan, Tokyo
Jolimont Capital Australia, Melbourne, Victoria
Lingyi Chuangzao Beijing, Beijing, China
MS Amlin England, London, United Kingdom
NETOPIA Bucharest, Bucuresti, Romania
Normandy Participations -
Si Chuan Venture Capital Chengdu, China, Sichuan
Softhouse -
Strait Capital Investment Group China, Shanghai
Yangzi Xinrui -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Neurolens

Eyewear
Health Care
Medical
Medical Device
Neuroscience
$67M12 Sep 2022 Costa Mesa, California, United States

Virtual Incision

Advanced Materials
Developer Platform
Health Care
Robotics
$46M30 Nov 2021 Lincoln, Nebraska, United States

Zerigo Health

Biopharma
Biotechnology
Health Care
Health Diagnostics
Medical
Medical Device
Therapeutics
$43M21 Oct 2021 San Diego, California, United States

Sydnexis

Manufacturing
Pharmaceutical
$45M10 Aug 2021 California, United States

Orasis Pharmaceuticals

Clinical Trials
Health Care
Medical
Pharmaceutical
$30M10 Sep 2020 Israel, Tel Aviv District, Israel

TearClear

Chemical Engineering
Medical Device
Pharmaceutical
$22M11 Aug 2020 Boston, Massachusetts, United States

Virtual Incision

Advanced Materials
Developer Platform
Health Care
Robotics
$20M08 Jan 2020 Lincoln, Nebraska, United States

Zerigo Health

Biopharma
Biotechnology
Health Care
Health Diagnostics
Medical
Medical Device
Therapeutics
$18M23 Oct 2019 San Diego, California, United States

Ambient Clinical Analytics

Analytics
Health Care
Medical
Software
$1M19 Jun 2018 Rochester, Minnesota, United States
News
Zerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions

– Zerigo Health announced a $43m Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer.
– The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital.
– This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
– Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Bluestem Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: